Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

The FDA has issued a warning about counterfeit Ozempic medications, sharing the lot numbers and serial numbers of products ...

Danish drugmaker Novo Nordisk said several hundred counterfeit units of its diabetes drug Ozempic were being distributed in ...

Novo Nordisk has invested 6.4bn Brazilian reais ($1.09bn) to expand its facility in Brazil as the company ramps up efforts to ...

Novo Nordisk agreed to pay up to $2 billion for the rights to a developmental weight-loss and obesity drug from Chinese pharmaceutical company The United Bio-Technology (Hengqin) Co., as it looks ...

Novo Nordisk ... health risks like cardiovascular disease, sleep apnea and liver disease. "It's clear that there is a very large market opportunity but it also takes a portfolio of products ...

Novo Nordisk will pay as much as $2 billion for a new obesity drug called UBT251 The company now holds the exclusive rights to develop, manufacture and sell the drug in much of the world It has ...

Novo Nordisk (NYSE: NVO) stock slipped 1.7% through ... At the same time, Hims & Hers Health stock is continuing to gain strength on the back of reports out last week, that the company's exit ...

The FDA and Novo Nordisk are testing the fake products to identify whether they ... manufactured in and was released from a Chinese lab. Health News // 1 day ago Michigan confirms first measles ...